GlassScriptPhysician profile
Larina Branch
NPI 1144678905
$5,323.41
in general payments reported to CMS, 2019-2025
30 companies · $1,665 in 2025
The $1,665 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $555 · 2022: $778 · 2023: $834 · 2024: $1,492 · 2025: $1,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,979 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,978.90 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,364.75 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $760.80 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $595.45 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.87 | 2021-2024 | Jardiance |
| Exact Sciences Corporation | $302.37 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novo Nordisk INC | $300.63 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Phathom Pharmaceuticals, INC. | $257.21 | 2024-2025 | Voquezna |
| Amgen INC. | $217.15 | 2021-2025 | Evenity, Repatha, Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.06 | 2021-2025 | Xifaxan |
| Astellas Pharma US INC | $128.89 | 2023-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $106.14 | 2021-2022 | |
| Dexcom, INC. | $95.38 | 2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $71.38 | 2024 | |
| Abbott Laboratories | $64.98 | 2023 | Freestyle Libre 3 |
| Dynavax Technologies Corporation | $59.74 | 2021-2024 | Heplisav-B |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $59.57 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $58.44 | 2022-2024 | Eliquis |
| Glaxosmithkline, LLC. | $57.42 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $50.60 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $49.82 | 2021 | |
| Eisai INC. | $31.71 | 2021 | |
| Boston Scientific Corporation | $30.76 | 2024 | Watchman Flx |
| Heartflow, INC. | $30.55 | 2025 | |
| Merck Sharp & Dohme LLC | $29.94 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $29.93 | 2021-2025 | Zoryve |
| Corcept Therapeutics | $28.28 | 2025 | Korlym |
| Horizon Therapeutics Plc | $20.70 | 2022 | |
| Abbvie INC. | $19.90 | 2025 | |
| Amarin Pharma, INC. | $15.50 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.49 | 2023 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larina Branch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.